Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5608092 | 0.88 | MAPK8 (0.55) | MAPK8HPGDLMNASMN1; SMN2GAA | |
| SCHEMBL4825735 | 0.84 | MAPK8 (0.55) | MAPK8HPGDLMNASMN1; SMN2ADORA3 | |
| SCHEMBL6433473 | 0.83 | PDE4A (0.59) | MAPK8HPGDGAA | |
| SCHEMBL5359759 | 0.83 | MAPK8 (0.54) | MAPK8HPGDLMNASMN1; SMN2GAA | |
| SCHEMBL6850749 | 0.83 | PDE4A (0.57) | MAPK8HPGDLMNASMN1; SMN2GAA | |
| SCHEMBL5405985 | 0.83 | MAPK8 (0.54) | MAPK8HPGDLMNASMN1; SMN2GAA | |
| SCHEMBL4825983 | 0.83 | MAPK8 (0.53) | MAPK8HPGDLMNASMN1; SMN2 | |
| SCHEMBL4826009 | 0.83 | MAPK8 (0.53) | MAPK8HPGDLMNASMN1; SMN2 | |
| SCHEMBL5395704 | 0.82 | GAA (0.46) | MAPK8GAA | |
| SCHEMBL6438916 | 0.82 | MAPK8 (0.56) | MAPK8HPGDLMNASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007517820-A | — | — | 2007-07-05 | — | — | JP | claimed |
| EP-1706118-A1 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON A SCOPINEESTER AND NICOTINAMIDE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2006-10-04 | — | — | EP | claimed |
| US-6953810-B2 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC (US) | 2005-10-11 | — | — | US | claimed |
| WO-2005067929-A1 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON A SCOPINEESTER AND NICOTINAMIDE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-28 | — | — | WO | claimed |
| US-20050154006-A1 | Pharmaceutical compositions based on a scopineester and nicotinamide derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | claimed |
| US-20040048903-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2004-03-11 | — | — | US | claimed |
| EP-1355884-A1 | NICOTINAMIDE BIARYL DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2003-10-29 | — | — | EP | claimed |
| US-20020193612-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2002-12-19 | — | — | US | claimed |
| WO-2002060875-A1 | NICOTINAMIDE BIARYL DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | claimed |
| EP-1706118-A1 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON A SCOPINEESTER AND NICOTINAMIDE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2006-10-04 | — | — | EP | disclosed |
| US-6953810-B2 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC (US) | 2005-10-11 | — | — | US | disclosed |
| WO-2005067929-A1 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON A SCOPINEESTER AND NICOTINAMIDE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-28 | — | — | WO | disclosed |
| US-20050154006-A1 | Pharmaceutical compositions based on a scopineester and nicotinamide derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
| US-6649633-B2 | For treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease | PFIZER INC | 2003-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193612-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | CBR1, CBR3, NOX1 | MAPK8 3111/4885HPGD 302/4885LMNA 1376/4885 |
| US-20050154006-A1 | Pharmaceutical compositions based on a scopineester and nicotinamide derivatives | NAMPT, NNT, XDH | MAPK8 2628/4885HPGD 98/4885LMNA 1251/4885 |
| US-20040048903-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | CBR1, CBR3, NOX1 | MAPK8 3287/4885HPGD 262/4885LMNA 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.